The European Medicine Agency (EMA) also gave the
green light to Vokanamet, a treatment for type 2 diabetes marketed
by Johnson & Johnson.
Recommendations for marketing approval by the EMA's Committee for
Medicinal Products for Human Use (CHMP) are normally endorsed by the
European Commission within a couple of months.
(Reporting by Paul Sandle; editing by
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.